Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 ...

In patients with moderate to severe ulcerative colitis, histologic improvement was greater with ozanimod 1 mg versus placebo at weeks 8 and 32

A greater proportion of patients achieved histologic remission at week 32 with ozanimod 1 mg versus placebo

Data shared in oral presentation at the 11th Congress of the European Crohn's and Colitis Organisation

(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that additional data of exploratory endpoints from the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe ulcerative colitis were presented at the 11^th Congress of the European Crohn's and Colitis Organisation (ECCO) in Amsterdam. Ozanimod is an investigational selective S1P 1 and 5 receptor modulator. ...

Source : http://me-newswire.net//news/17378/en...